|

Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract

RECRUITINGSponsored by M.D. Anderson Cancer Center
Actively Recruiting
SponsorM.D. Anderson Cancer Center
Started2026-09-10
Est. completion2036-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Eligibility Criteria

Participants must meet all of the following criteria for enrollment:

1. Age 18 years or older at the time of consent.
2. Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy.
3. Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations.
4. Able to understand and personally provide informed consent.
5. Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document.

Exclusion Criteria

1. Age younger than 18 years.
2. Unable to understand the study information or unable to personally provide informed consent.
3. Declines participation.
4. No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives.
5. Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately.
6. Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.

Conditions2

CancerUrothelial Carcinoma

Locations1 site

UT MD Anderson Cancer Center
Houston, Texas, 77030
Bryon Lee, MD713-792-3250BHLee@mdanderson.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.